ENTRY       D01223                      Drug
NAME        Capecitabine (JAN/USP/INN);
            Xeloda (TN)
PRODUCT     XELODA (Genentech)
            XELODA (H2-Pharma)
  GENERIC   CAPECITABINE (Accord Healthcare)
            CAPECITABINE (American Health Packaging)
            CAPECITABINE (Amneal Pharmaceuticals LLC)
            CAPECITABINE (Areva Pharmaceuticals)
            CAPECITABINE (Ascend Laboratories)
            CAPECITABINE (Aurobindo Pharma Limited)
            CAPECITABINE (BluePoint Laboratories)
            CAPECITABINE (CELLTRION USA)
            CAPECITABINE (Cipla USA)
            CAPECITABINE (Dr. Reddy's Laboratories Limited)
            CAPECITABINE (Golden State Medical Supply)
            CAPECITABINE (Golden State Medical Supply)
            CAPECITABINE (Hikma Pharmaceuticals USA)
            CAPECITABINE (Lifestar Pharma LLC)
            CAPECITABINE (MSN LABORATORIES PRIVATE LIMITED)
            CAPECITABINE (NORTHSTAR RXLLC)
            CAPECITABINE (Novadoz Pharmaceuticals LLC)
            CAPECITABINE (Quallent Pharmaceuticals Health LLC)
            CAPECITABINE (Rising Pharmaceuticals)
            CAPECITABINE (Sun Pharmaceutical Industries)
            CAPECITABINE (Teva Pharmaceuticals USA)
            CAPECITABINE 150MG (Armas Pharmaceuticals)
            CAPECITABINE 500MG (Armas Pharmaceuticals)
FORMULA     C15H22FN3O6
EXACT_MASS  359.1493
MOL_WEIGHT  359.3501
CLASS       Antineoplastic
             DG02018  Antimetabolite
              DG01958  Nucleic acid derivative, antineoplastic
               DG01935  Fluoropyrimidine antineoplastic
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
REMARK      Same as: C12650
            Therapeutic category: 4223
            ATC code: L01BC06
            Product: D01223<JP/US>
EFFICACY    Antineoplastic, Antimetabolite
  DISEASE   Colorectal cancer [DS:H00020]
            Breast cancer [DS:H00031]
            Gastric cancer [DS:H00018]
            Esophageal cancer [DS:H00017]
            Pancreatic cancer [DS:H00019]
COMMENT     Active form of prodrug: Fluorouracil [DR:D00584]
TARGET      TYMS [HSA:7298] [KO:K00560]
  PATHWAY   hsa00240(7298)  Pyrimidine metabolism
            hsa00670(7298)  One carbon pool by folate
METABOLISM  Enzyme: CYP2C9 [HSA:1559]
INTERACTION  
STR_MAP     map07041  Antineoplastics - antimetabolic agents
OTHER_MAP   map00983  Drug metabolism - other enzymes
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01B ANTIMETABOLITES
                L01BC Pyrimidine analogues
                 L01BC06 Capecitabine
                  D01223  Capecitabine (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antimetabolites
               Capecitabine
                D01223  Capecitabine (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               422  Antimetabolites
                4223  Fluorouracils
                 D01223  Capecitabine (JAN/USP/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02018  Antimetabolite
               DG01958  Nucleic acid derivative, antineoplastic
                DG01935  Fluoropyrimidine antineoplastic
                 D01223  Capecitabine
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               D01223  Capecitabine
            Drug classes [BR:br08332]
             Antineoplastic
              DG02018  Antimetabolite
               D01223  Capecitabine
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Transferases (EC2)
               Methyltransferases
                TYMS
                 D01223  Capecitabine (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D01223
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01223
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D01223
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D01223
DBLINKS     CAS: 154361-50-9
            PubChem: 7848286
            ChEBI: 31348
            LigandBox: D01223
            NIKKAJI: J949.163E
ATOM        25
            1   C1y C    11.2700  -21.5600
            2   C1y C    12.6700  -21.5600
            3   C1y C    13.1600  -20.2300
            4   O2x O    11.9700  -19.4600
            5   C1y C    10.8500  -20.2300
            6   C1a C     9.5200  -19.8100
            7   O1a O    10.4300  -22.7500
            8   O1a O    13.5100  -22.7500
            9   N4y N    14.4900  -19.8100
            10  C8y C    15.6800  -20.5100
            11  N5x N    16.9400  -19.8100
            12  C8y C    16.9400  -18.4100
            13  C8y C    15.7500  -17.7100
            14  C8x C    14.4900  -18.4100
            15  O5x O    15.6800  -21.9100
            16  X   F    15.7500  -16.3800
            17  N1b N    18.1300  -17.7100
            18  C7a C    19.3200  -18.4100
            19  O7a O    20.5100  -17.7100
            20  C1b C    21.7000  -18.4100
            21  C1b C    22.8900  -17.7100
            22  C1b C    24.0800  -18.4100
            23  C1b C    25.2700  -17.7100
            24  C1a C    26.4600  -18.4100
            25  O6a O    19.3200  -19.8100
BOND        26
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     1   5 1
            6     5   6 1 #Up
            7     1   7 1 #Down
            8     2   8 1 #Down
            9     3   9 1 #Up
            10    9  10 1
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14   13  14 2
            15    9  14 1
            16   10  15 2
            17   13  16 1
            18   17  18 1
            19   17  12 1
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   23  24 1
            26   18  25 2
///
